Phase 3 Trial of Optune, Temozolomide, and Pembrolizumab in Newly Diagnosed Glioblastoma
The EF‑41 / KEYNOTE D58 Phase 3 trial evaluates whether adding pembrolizumab to Optune and temozolomide improves overall survival and progression‑free survival in newly diagnosed glioblastoma patients.
A randomized, double‑blind, place‑bo‑controlled Phase 3 study is assessing the efficacy and safety of Optune, maintenance temozolomide, and pembrolizumab versus Optune plus temozolomide with placebo in adult patients with newly diagnosed glioblastoma after surgery and radiotherapy.
Incorporating the anti‑PD‑1 agent pembrolizumab into the standard glioblastoma treatment regimen may provide a new therapeutic strategy to improve patient survival outcomes.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma